Vascular Biogenics Ltd (VBLT)

[mantoo123]

You should not invest in biotech sums that you are not prepared to lose.

Even if VB-111 is approved by the FDA, it does not necessarily mean that it will be adopted by doctors as a treatment. Approved drugs fail in the market. Dr. Harats hinted that VBL was good in creating innovative drugs but not necessarily good in marketing.

Oren, you seem to focus on the elements that make VBL shine but seem to ignore the potential pitfalls ahead. The road for VBL is still long albeit VERY promising.

In light of the above caveats, I also think that current VBLT valuation is very low. I am already invested in VBLT to my limit.